文献速递免疫规划传染病防控与疫情报告

母源抗体对重组新城疫病毒载体禽流感疫苗的抑制效应

Maternal antibody inhibition of recombinant Newcastle disease virus vectored vaccine in a primary or booster avian influenza vaccination program of broiler chickens.
PubMed 文献 · Vaccine · 2018-09-18

本研究在具有母源抗体(MDA)的肉鸡中评估喷雾型重组新城疫病毒载体H5疫苗(rNDV-H5)与重组火鸡疱疹病毒载体H5疫苗(rHVT-H5)对同源高致病性禽流感病毒(HPAIV)攻毒的保护效果。结果显示,接种时AIV和/或NDV母源抗体存在可阻止rNDV-H5初次或加强免疫产生保护性免疫,而AIV母源抗体对rHVT-H5效果影响极小。

要点

  • 接种时AIV和/或NDV母源抗体存在可阻止rNDV-H5初次或加强免疫产生保护性免疫,攻毒后100%死亡。
  • rNDV-H5接种时母源抗体已完全降至不可检出水平的鸡群,5周龄攻毒后存活率达70-78%。
  • rHVT-H5在1日龄接种时,无论是否3周龄加强rNDV-H5,攻毒前均达到保护性AIV抗体水平,全部存活。

核心结论

  • AIV母源抗体对rHVT-H5疫苗效果影响极小,但接种时AIV和/或NDV母源抗体存在可阻止rNDV-H5初次或加强免疫诱导保护性免疫。

研究设计与样本

  • 实验1:3周龄喷雾接种rNDV-H5,5周龄同源HPAIV攻毒,比较MDA:AIV-NDV+与MDA:AIV+NDV+商品肉鸡。
  • 实验2:1日龄或3周龄接种rHVT-H5和rNDV-H5,5周龄攻毒,评估母源抗体对免疫效果的影响。

主要发现

  • 实验1中,所有假接种鸡无AIV抗体且攻毒后死亡;rNDV-H5接种组母源抗体已降至不可检出,5周龄攻毒后存活率70-78%,排毒显著减少。
  • 实验2中,所有假接种鸡无AIV抗体且攻毒后死亡;rHVT-H5(1d)接种组无论是否3周龄加强rNDV-H5,攻毒前AIV抗体达保护水平,全部存活且排毒显著减少。
  • 实验2中,rNDV-H5接种鸡在接种时(1日龄和/或3周龄)存在AIV和/或NDV母源抗体,5周龄前未产生保护性免疫应答,攻毒后100%死亡。

关键数值与推荐

  • rNDV-H5接种组5周龄攻毒后存活率70-78%,排毒较假接种组显著减少。
  • rHVT-H5(1d)接种组攻毒前AIV抗体达保护水平,攻毒后全部存活。
  • 接种时存在AIV和/或NDV母源抗体的rNDV-H5接种鸡攻毒后死亡率100%。

临床怎么用

  • 在HPAIV地方流行国家,肉鸡常携带NDV和H5 HPAIV母源抗体,需考虑母源抗体对重组载体疫苗主动免疫的影响。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Maternally-derived antibodies (MDA) provide early protection from disease, but may interfere with active immunity in young chicks. In highly pathogenic avian influenza virus (HPAIV)-enzootic countries, broiler chickens typically have MDA to Newcastle disease virus (NDV) and H5 HPAIV, and their impact on active immunity from recombinant vectored vaccines is unclear. We assessed the effectiveness of a spray-applied recombinant NDV vaccine with H5 AIV insert (rNDV-H5) and a recombinant turkey herpesvirus (HVT) vaccine with H5 AIV insert (rHVT-H5) in commercial broilers with MDA to NDV alone (MDA:AIV-NDV+) or to NDV plus AIV (MDA:AIV+NDV+) to provide protection against homologous HPAIV challenge. In Experiment 1, chicks were spray-vaccinated with rNDV-H5 at 3 weeks (3w) and challenged at 5 weeks (5w). All sham-vaccinated progeny lacked AIV antibodies and died following challenge. In rNDV-H5 vaccine groups, AIV and NDV MDA had completely declined to non-detectable levels by vaccination, enabling rNDV-H5 spray vaccine to elicit a protective AIV antibody response by 5w, with 70-78% survival and significant reduction of virus shedding compared to shams. In Experiment 2, progeny were vaccinated with rHVT-H5 and rNDV-H5 at 1 day (1d) or 3w and challenged at 5w. All sham-vaccinated progeny lacked AIV antibodies and died following challenge. In rHVT-H5(1d) vaccine groups, irrespective of rNDV-H5(3w) boost, AIV antibodies reached protective levels pre-challenge, as all progeny survived and virus shedding significantly decreased compared to shams. In contrast, rNDV-H5-vaccinated progeny had AIV and/or NDV MDA at the time of vaccination (1d and/or 3w) and failed to develop a protective immune response by 5w, resulting in 100% mortality after challenge. Our results demonstrate that MDA to AIV had minimal impact on the effectiveness of rHVT-H5, but MDA to AIV and/or NDV at the time of vaccination can prevent development of protective immunity from a primary or booster rNDV-H5 vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bertran K, Lee DH, Criado MF, et al. Maternal antibody inhibition of recombinant Newcastle disease virus vectored vaccine in a primary or booster avian influenza vaccination program of broiler chickens. Vaccine. 2018. PMID: 30241684. doi:10.1016/j.vaccine.2018.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。